Company · CIK 1785279
Metagenomi Therapeutics, Inc.
| CIK | 1785279 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Business address | CA |
| Listed | MGX (Nasdaq) |
| First annual or quarterly report | 2024-03-27 |
Offerings
2 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-285867 | 2025-03-17 | 2025-03-25 | 2 | |
| 333-276413 | 2024-01-05 | 2024-02-12 | 6 |
Filings
9| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2025-03-25 | EFFECTDeclared effective | 333-285867 | 9999999995-25-000782 |
| 2025-03-17 | S-3Shelf registered | 333-285867 | 0000950170-25-040421 |
| 2024-02-12 | 424B4Final prospectus | 333-276413 | 0001193125-24-031007 |
| 2024-02-08 | EFFECTDeclared effective | 333-276413 | 9999999995-24-000355 |
| 2024-02-07 | S-1/AAmendment | 333-276413 | 0001193125-24-026662 |
| 2024-02-05 | S-1/AAmendment | 333-276413 | 0001193125-24-023377 |
| 2024-01-08 | S-1/AAmendment | 333-276413 | 0001193125-24-003810 |
| 2024-01-05 | S-1Registration filed | 333-276413 | 0001193125-24-003477 |
| 2023-08-03 | DRSDraft made public | 377-06800 | 0000950123-23-006615 |